<DOC>
	<DOCNO>NCT01000831</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness ( immune response ) one two dos adjuvanted H1N12009 influenza vaccine young child . An adjuvant additive boost immune response . The study enroll 300 child ( age 6-35 month ) . Participants receive 2 dos adjuvanted H1N12009 vaccine 3 week apart . Study procedures include : medical history , blood sample complete memory aid . Participants involve study related procedure approximately 6 week .</brief_summary>
	<brief_title>Rapid Evaluation Pandemic H1N1 Influenza Vaccines Young Children</brief_title>
	<detailed_description>The goal study determine one two dos H1N12009 influenza vaccine need young child , population group high risk influenza infection subsequent hospitalization . The objective study two-fold : 1 . To compare safety immunogenicity 1 2 dos adjuvanted H1N12009 influenza vaccine child 6-35 month age . 2 . To conduct trial soon vaccines become available share observation health official public soon possible .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent provide subject parent legal guardian Children age 635 month Allergies egg , thimerosal , gentamicin sulphate latex Lifethreatening reaction previous Flu vaccine Bleeding disorder Pregnancy Receipt blood blood product past 3 month Chronic illness could interfere trial participation Compromised immune system Previous labconfirmed H1N12009 infection Receipt H1N12009 vaccine Receipt Seasonal Influenza vaccine since March 2009</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>vaccine</keyword>
	<keyword>influenza</keyword>
	<keyword>H1N1 influenza vaccine</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>Arepanrix</keyword>
</DOC>